Other Events ·
Madrigal Pharmaceuticals, Inc. announced several governance and compensation updates following its June 17, 2026…
MDGLMadrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. announced several governance and compensation updates following its June 17, 2026, annual meeting. Stockholders approved the 2026 Stock Plan and the 2026 Employee Stock Purchase Plan. The Board also approved a new Nonqualified Deferred Compensation Plan effective August 1, 2026, allowing key employees to defer significant portions of salary and bonuses. Additionally, Dr. Rebecca Taub will transition from an employee to a consultant effective July 1, 2026, providing scientific guidance for MASH programs for $100,000 annually while maintaining her board seat. The company also re-elected three Class I directors and ratified PricewaterhouseCoopers LLP as its independent auditor. Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing treatments for liver diseases.